StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

CRISPR Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -3368.7%. For fiscal 2025 it was -16569.8%, against -981.5% the year before. The highest annual figure on record is 41.3% in fiscal 2021.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-16569.8%−15588.2
FY2024Dec 31, 2024-981.5%−940.2
FY2023Dec 31, 2023-41.4%+54230.3
FY2022Dec 31, 2022-54271.7%−54313.0
FY2021Dec 31, 202141.3%+48562.1
FY2020Dec 31, 2020-48520.9%−48543.9
FY2019Dec 31, 201923.1%+5304.2
FY2018Dec 31, 2018-5281.1%−5114.3
FY2017Dec 31, 2017-166.7%+282.1
FY2016Dec 31, 2016-448.8%+9876.3
FY2015Dec 31, 2015-10325.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-895.3%+22484.6
Q1 FY2026Mar 31, 2026-8431.5%+7290.6
Q4 FY2025Dec 31, 2025-15117.2%−15012.7
Q3 FY2025Sep 30, 2025-11973.1%+2303.0
Q2 FY2025Jun 30, 2025-23379.9%+1070.4
Q1 FY2025Mar 31, 2025-15722.1%+7411.1
Q4 FY2024Dec 31, 2024-104.5%−148.9
Q3 FY2024Sep 30, 2024-14276.1%−14165.0
Q2 FY2024Jun 30, 2024-24450.3%−24397.2
Q1 FY2024Mar 31, 2024-23133.1%+1819783.5
Q4 FY2023Dec 31, 202344.4%+185734.8
Q2 FY2023Jun 30, 2023-111.1%+117505.4
Q1 FY2023Mar 31, 2023-53.1%+19012.6
Q4 FY2022Dec 31, 2022-1842916.7%−1841821.6
Q3 FY2022Sep 30, 2022-185690.4%−170259.2
Q2 FY2022Jun 30, 2022-117616.5%−117700.7
Q1 FY2022Mar 31, 2022-19065.6%+1929.4
Q4 FY2021Dec 31, 2021-1095.0%+27834.4
Q3 FY2021Sep 30, 2021-15431.2%+47027.6
Q2 FY2021Jun 30, 202184.3%+181120.7
Q1 FY2021Mar 31, 2021-20995.0%+23419.7
Q4 FY2020Dec 31, 2020-28929.5%−28969.1
Q3 FY2020Sep 30, 2020-62458.8%−62524.1
Q2 FY2020Jun 30, 2020-181036.4%−164149.9
Q1 FY2020Mar 31, 2020-44414.6%−29656.1
Q4 FY2019Dec 31, 201939.7%+41422.3
Q3 FY2019Sep 30, 201965.3%+9072.6
Q2 FY2019Jun 30, 2019-16886.5%−13358.9
Q1 FY2019Mar 31, 2019-14758.5%−12674.6
Q4 FY2018Dec 31, 2018-41382.6%−41383.0
Q3 FY2018Sep 30, 2018-9007.3%−7972.2
Q2 FY2018Jun 30, 2018-3527.6%−2904.6
Q1 FY2018Mar 31, 2018-2083.9%−1289.5
Q4 FY2017Dec 31, 20170.4%−729.0
Q3 FY2017Sep 30, 2017-1035.1%−87.4
Q2 FY2017Jun 30, 2017-623.0%–
Q1 FY2017Mar 31, 2017-794.5%–
Q4 FY2016Dec 31, 2016729.5%–
Q3 FY2016Sep 30, 2016-947.7%–

More CRISPR Therapeutics figures

See a number that looks wrong?